Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Stahmann

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Therapeutic Advances in Neurological Disorders|March 18, 2024
Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populationsAlexander Stahmann, Elaine Craig, David Ellenberger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2018
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registryPaulus Stefan Rommer, Kerstin Eichstädt, David Ellenberger, et al.
BMJ Open|July 8, 2026
Application of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in the clinical management of multiple sclerosis (NeuroFilMS): a protocol for an observational cohort studyRebekka Rust, Sara Samadzadeh, Anna-Lena Röper, et al.
Neurological Research and Practice|May 18, 2025
From routine to selective: how updated MRI guidelines reshape gadolinium use in GermanyMarc Pawlitzki, Alexander Stahmann, Niklas Frahm, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis RegistryStefan J Blaschke, David Ellenberger, Peter Flachenecker, et al.
Vaccines|December 23, 2023
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational StudyFiras Fneish, Niklas Frahm, Melanie Peters, et al.
Journal of Clinical Medicine|June 10, 2023
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational StudyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Multiple Sclerosis and Related Disorders|January 29, 2022
Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in GermanyJakob Holstiege, Manas K Akmatov, Kerstin Klimke, et al.
Neurology and Therapy|January 12, 2022
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS RegistryNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Deutsches Arzteblatt International|June 24, 2025
Communication, Coordination, and Security for People With Multiple Sclerosis (COCOS-MS): A Randomized, Phase II Trial of Cross-Sectoral Care and Case ManagementHeidrun Golla, Veronika Dunkl, Anne Dorr, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Therapeutic Advances in Neurological Disorders|March 18, 2024
Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populationsAlexander Stahmann, Elaine Craig, David Ellenberger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2018
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registryPaulus Stefan Rommer, Kerstin Eichstädt, David Ellenberger, et al.
BMJ Open|July 8, 2026
Application of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) as biomarkers in the clinical management of multiple sclerosis (NeuroFilMS): a protocol for an observational cohort studyRebekka Rust, Sara Samadzadeh, Anna-Lena Röper, et al.
Neurological Research and Practice|May 18, 2025
From routine to selective: how updated MRI guidelines reshape gadolinium use in GermanyMarc Pawlitzki, Alexander Stahmann, Niklas Frahm, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2021
Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis RegistryStefan J Blaschke, David Ellenberger, Peter Flachenecker, et al.
Vaccines|December 23, 2023
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational StudyFiras Fneish, Niklas Frahm, Melanie Peters, et al.
Journal of Clinical Medicine|June 10, 2023
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational StudyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Multiple Sclerosis and Related Disorders|January 29, 2022
Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in GermanyJakob Holstiege, Manas K Akmatov, Kerstin Klimke, et al.
Neurology and Therapy|January 12, 2022
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS RegistryNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Deutsches Arzteblatt International|June 24, 2025
Communication, Coordination, and Security for People With Multiple Sclerosis (COCOS-MS): A Randomized, Phase II Trial of Cross-Sectoral Care and Case ManagementHeidrun Golla, Veronika Dunkl, Anne Dorr, et al.
Pageof 5